FDA
-
-
-
-
-
-
-
Eli Lilly to acquire AtaiBeckley for up to $3.8B
-
-
-
-
-
-
-
/C O R R E C T I O N -- Eli Lilly and Company/
-
-
-
-
-
-
-
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
-
-
-
-
-
-
-
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
-
-
-
-
-
-
-
Weight Watchers integrates with Eli Lilly's LillyDirect platform
-
-
-
-
-
-
-
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
-
-
-
-
-
-
-
Lilly's retatrutide shows significant weight loss in phase 3 trial
-
327,805 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

